|
Name |
beta-Chamigrene
|
| Molecular Formula | C15H24 | |
| IUPAC Name* |
5,5,9-trimethyl-1-methylidenespiro[5.5]undec-9-ene
|
|
| SMILES |
CC1=CCC2(CC1)C(=C)CCCC2(C)C
|
|
| InChI |
InChI=1S/C15H24/c1-12-7-10-15(11-8-12)13(2)6-5-9-14(15,3)4/h7H,2,5-6,8-11H2,1,3-4H3
|
|
| InChIKey |
WLNGPDPILFYWKF-UHFFFAOYSA-N
|
|
| Synonyms |
.beta.-Chamigrene; Chamigrene; Chamigren; 3,7,7-trimethyl-11-methylidenespiro[5.5]undec-2-ene; Spiro[5.5]undec-2-ene, 3,7,7-trimethyl-11-methylene-, (-)-; CHEBI:61744; DB-065465; FT-0773907; 3,7,7-Trimethyl-11-methylenespiro[5.5]undeca-2-ene; 5,5,9-trimethyl-1-methylidenespiro[5.5]undec-9-ene; Q27131361; 3,7,7-Trimethyl-11-methylenespiro[5.5]undec-2-ene #; Spiro[5.5]undec-2-ene, 3,7,7-trimethyl-11-methylene-, (R)-
|
|
| CAS | NA | |
| PubChem CID | 29073 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 204.35 | ALogp: | 4.7 |
| HBD: | 0 | HBA: | 0 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
| Heavy Atoms: | 15 | QED Weighted: | 0.472 |
| Caco-2 Permeability: | -4.501 | MDCK Permeability: | 0.00001170 |
| Pgp-inhibitor: | 0.653 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.924 |
| 30% Bioavailability (F30%): | 0.473 |
| Blood-Brain-Barrier Penetration (BBB): | 0.236 | Plasma Protein Binding (PPB): | 94.16% |
| Volume Distribution (VD): | 3.43 | Fu: | 5.84% |
| CYP1A2-inhibitor: | 0.566 | CYP1A2-substrate: | 0.636 |
| CYP2C19-inhibitor: | 0.605 | CYP2C19-substrate: | 0.929 |
| CYP2C9-inhibitor: | 0.411 | CYP2C9-substrate: | 0.894 |
| CYP2D6-inhibitor: | 0.024 | CYP2D6-substrate: | 0.683 |
| CYP3A4-inhibitor: | 0.333 | CYP3A4-substrate: | 0.215 |
| Clearance (CL): | 9.268 | Half-life (T1/2): | 0.058 |
| hERG Blockers: | 0.022 | Human Hepatotoxicity (H-HT): | 0.554 |
| Drug-inuced Liver Injury (DILI): | 0.03 | AMES Toxicity: | 0.011 |
| Rat Oral Acute Toxicity: | 0.1 | Maximum Recommended Daily Dose: | 0.101 |
| Skin Sensitization: | 0.05 | Carcinogencity: | 0.849 |
| Eye Corrosion: | 0.328 | Eye Irritation: | 0.96 |
| Respiratory Toxicity: | 0.954 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001135 | ![]() |
0.577 | D0Z1XD | ![]() |
0.244 | ||
| ENC002199 | ![]() |
0.390 | D0G8BV | ![]() |
0.235 | ||
| ENC001663 | ![]() |
0.390 | D07BSQ | ![]() |
0.235 | ||
| ENC001077 | ![]() |
0.377 | D0K0EK | ![]() |
0.235 | ||
| ENC002337 | ![]() |
0.371 | D06XMU | ![]() |
0.235 | ||
| ENC001813 | ![]() |
0.367 | D0L2LS | ![]() |
0.233 | ||
| ENC001826 | ![]() |
0.367 | D0A2AJ | ![]() |
0.230 | ||
| ENC001080 | ![]() |
0.367 | D02CNR | ![]() |
0.229 | ||
| ENC001630 | ![]() |
0.367 | D0F2AK | ![]() |
0.227 | ||
| ENC001565 | ![]() |
0.367 | D04GJN | ![]() |
0.225 | ||